胰腺癌分子匹配治疗的总体生存:Know Your Tumor注册试验回顾分析
该回顾分析纳入Know Your Tumor注册项目中1856例胰腺癌患者,1082例获得分子检测报告,282例(26%)存在可操作分子改变,677例有结局数据。
要点
- 可操作分子改变在胰腺癌中占26%(282/1082)。
核心结论
- 真实世界数据提示精准医学可对胰腺癌生存产生实质性影响。
- 靶向致癌驱动及DNA损伤应答修复通路的分子指导治疗值得前瞻性评估。
研究设计与样本
- 回顾性分析Know Your Tumor注册项目,纳入18岁及以上活检确诊的任何分期胰腺癌患者。
- 从晚期疾病初诊至死亡计算中位总生存,比较可操作突变者接受匹配治疗与未接受匹配治疗的生存差异。
主要发现
- 1856例患者中1082例(58%)获得基于分子检测结果的个性化报告。
- 282例(26%)样本存在可操作分子改变。
- 677例有结局数据者中189例存在可操作分子改变。
- 中位随访383天(IQR 214-588)。
临床怎么用
- 对胰腺癌患者可考虑多组学分子谱检测以识别可操作改变。
- 存在可操作改变者,优先推荐分子匹配治疗或临床试验。
局限性
- 回顾性设计,非随机比较,存在选择偏倚可能。
- 接受匹配治疗的患者样本量较小(n=46)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: About 25% of pancreatic cancers harbour actionable molecular alterations, defined as molecular alterations for which there is clinical or strong preclinical evidence of a predictive benefit from a specific therapy. The Know Your Tumor (KYT) programme includes US patients with pancreatic cancer and enables patients to undergo commercially available multi-omic profiling to provide molecularly tailored therapy options and clinical trial recommendations. We sought to determine whether patients with pancreatic cancer whose tumours harboured such actionable molecular alterations and who received molecularly matched therapy had a longer median overall survival than similar patients who did not receive molecularly matched therapy. METHODS: In this retrospective analysis, treatment history and longitudinal survival outcomes were analysed in patients aged 18 years or older with biopsy-confirmed pancreatic cancer of any stage, enrolled in the KYT programme and who received molecular testing results. Since the timing of KYT enrolment varied for each patient, the primary outcome measurement of median overall survival was calculated from the initial diagnosis of advanced disease until death. We compared median overall survival in patients with actionable mutations who were treated with a matched therapy versus those who were not treated with a matched therapy. FINDINGS: Of 1856 patients with pancreatic cancer who were referred to the KYT programme between June 16, 2014, and March 31, 2019, 1082 (58%) patients received personalised reports based on their molecular testing results. Actionable molecular alterations were identified in 282 (26%) of 1082 samples. Among 677 patients for whom outcomes were available, 189 had actionable molecular alterations. With a median follow-up of 383 days (IQR 214-588), those patients with actionable molecular alterations who received a matched therapy (n=46) had significantly longer median overall survival than did those patients who only received unmatched therapies (n=143; 2·58 years [95% CI 2·39 to not reached] vs 1·51 years [1·33-1·87]; hazard ratio 0·42 [95% CI 0·26-0·68], p=0·0004). The 46 patients who received a matched therapy also had significantly longer overall survival than the 488 patients who did not have an actionable molecular alteration (2·58 years [95% CI 2·39 to not reached] vs 1·32 years [1·25-1·47]; HR 0·34 [95% CI 0·22-0·53], p<0·0001). However, median overall survival did not differ between the patients who received unmatched therapy and those without an actionable molecular alteration (HR 0·82 [95% CI 0·64-1·04], p=0·10). INTERPRETATION: These real-world outcomes suggest that the adoption of precision medicine can have a substantial effect on survival in patients with pancreatic cancer, and that molecularly guided treatments targeting oncogenic drivers and the DNA damage response and repair pathway warrant further prospective evaluation. FUNDING: Pancreatic Cancer Action Network and Perthera.
引用
- Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020. PMID: 32135080. doi:10.1016/S1470-2045(20)30074-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。